Physician profile
Soly Melamed
NPI 1619031697
$386.75
in general payments reported to CMS, 2019-2025
11 companies · $55.42 in 2025
The $55.42 reported for 2025 was less than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.90 · 2020: $66.39 · 2021: $12.33 · 2022: $31.18 · 2023: $150 · 2024: $16.69 · 2025: $55.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $221.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $97.06 | 2023 | Wavewriter Alpha Prime 16 |
| Neurelis, INC. | $69.60 | 2023-2025 | Valtoco |
| Greenwich Biosciences, INC. | $39.12 | 2019 | |
| Ucb, INC. | $37.97 | 2020 | |
| Mannkind Corporation | $31.18 | 2022 | |
| Upsher-Smith Laboratories LLC | $28.42 | 2020 | |
| Novartis Pharmaceuticals Corporation | $21.53 | 2025 | |
| Currax Pharmaceuticals LLC | $17.07 | 2023 | Onzetra Xsail |
| Lilly USA, LLC | $16.69 | 2024 | Jardiance, Zepbound |
| Amgen INC. | $15.78 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Soly Melamed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.